ADHD Therapeutics Market Share to Witness Excellent Long-Term Growth Outlook
This report covers Global “ADHD Therapeutics Market Research Report- Forecast To 2024” from the bottom line, starting from its definition. Later, it segments the market on various criteria to give a depth of understanding on the various product types and pricing structures and applications.
Attention deficit
hyperactivity disorder (ADHD) is a neurodevelopmental disorder with a group of
behavioral symptoms that include hyperactivity, inattentiveness and
impulsiveness. The symptoms of ADHD begin in childhood and can continue through
adolescence and adulthood. As per the report published by Market Research
Future (MRFR), the global ADHD therapeutics market is registered to grow
steadily till the end of 2024.
The symptoms of ADHD such
as lack of attention, hyperactivity and impulsivity hamper proper functioning
and development of an individual. Increasing awareness regarding
neurodevelopmental disorders and easy availability of diagnostic guidelines
over the internet is projected to boost the growth of the global ADHD
therapeutics market.
However, underdiagnosis of
ADHD due to the existence of comorbid conditions in children, lack of awareness
and low availability of non-stimulant drugs to treat ADHD in various regions
are likely to hamper the expansion of the global ADHD therapeutics market
during the forecast period.
The global ADHD Therapeutics Market Share has been segmented on the basis of drug type and
distribution channel. Based on drug type, the ADHD therapeutics market is
segmented into stimulants and non-stimulants. The stimulants segment is
sub-segmented into amphetamine, methylphenidate, dextroamphetamine,
lisdexamfetamine and others. The non-stimulants segment is sub-segmented into
atomoxetine, bupropion, guanfacine and clonidine
Based on distribution
channel, the ADHD therapeutics market is segmented into hospitals, clinics,
pharmacies, research laboratories and others.
Geographically, the global
ADHD therapeutics market is segmented into four major regions such as North
America, Europe, Asia Pacific and the Middle East and Africa. The ADHD
therapeutics market in the North America region accounts for the dominant share
in the global ADHD therapeutics market owing to the increasing prevalence of
ADHD in the children and high healthcare expenditure by the population in this
region. The ADHD therapeutics market in the Europe region is projecting
significant growth owing to the increased research and development for the
introduction of more effective drugs in this region. The Asia Pacific region is
anticipated to grow at a notable pace in the coming years due to increased
awareness regarding ADHD and its available treatments. Whereas, the Middle East
and Africa region is projecting steady growth in the global ADHD market owing
to the low awareness and poor primary health care in the underdeveloped areas
of this region.
The prominent players
profiled by MRFR in the report on the global ADHD therapeutics market are
Concordia International Corp., Eli Lilly and Company, Highland Therapeutics
Inc., Janssen Global Services LLC, NEOS Therapeutics Inc., Novartis AG, Noven
Pharmaceuticals Inc., Pfizer Inc., Shire, Teva Pharmaceutical and others.
At Market
Research Future (MRFR), we enable our customers to unravel the complexity of
various industries through our Cooked Research Report (CRR), Half-Cooked
Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research
(CFR), and Market Research & Consulting Services.
Akash Anand
Market
Research Future
+1 646 845
9312
Comments
Post a Comment